Bevifibatide Citrate

枸橼酸倍维巴肽

Report date: 2026/04/15 20:02:38
NME

Base Information

Drug NameBevifibatide Citrate
Drug Alias Name巴替非班Batifiban贝塔宁BETAGRINBAT-2094 +[6] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionIntegrin alpha-IIb/beta-3 antagonists
TargetsIntegrin alpha-IIb/beta-3
Therapy Area/IndicationsThrombosisNon-ST Elevated Myocardial InfarctionMyocardial Infarction +[7] 
Global Approved IndicationsAcute Coronary Syndrome
Approved Indications in ChinaAcute Coronary Syndrome
Original Approved Country/TerritoryMainland China
Original Approved Date2024/06/25
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBio-Thera Solutions Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBio-Thera Solutions LtdLepu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAcute Coronary Syndrome
Inactive IndicationsThrombosisNon-ST Elevated Myocardial InfarctionMyocardial Infarction +[6] 

Other Information

ATC CodeN/A
Related LinksN/A